Neoadjuvant chemotherapy in the treatment of advanced ovarian cancer: Impact on the quality of interval surgery and disease-free survival [Chimiothérapie néoadjuvante dans les cancers ovariens avancés: Impact sur la qualité de la chirurgie d'intervalle et sur la survie sans rechute]

摘要

The presence of residual tumour measuring less than 1 cm after debulking surgery for advanced ovarian cancer is the most significant prognostic factor. Does interval surgery after three to six cycles of chemotherapy increase the resection rate of lesions measuring less than 1 cm? The aim of this study was to compare the rate of these resections and disease-free survival (DFS) in an interval surgery group (A) and a cytoreductive surgery group (B) at the end of treatment. The rates of resection of tumours measuring less that 1 cm, considered the optimal treatment, are, respectively, 88.4 and 65.1% (P < 0.05) in groups A and B. The difference in DFS after 3 years is not significant but tends toward significance (P = 0.08). Interval surgery is a good alternative for platinum-resistant patients and decreases the morbidity of patients for whom debulking surgery is contraindicated.